Adjuvants for influenza vaccine

Research in Immunology

Volumn 149, Issue 1, 1998, Pages 19-23

  Bouveret Le Cam, N N ^a   Ronco, J ^a   Francon, A ^a   Blondeau, C ^a   Fanget, B ^a  

^a Pasteur Merieux Connaught   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0040577732     PISSN: 09232494     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-2494(98)80037-0     Document Type: Article

References (8)

1. LaMontagne, J.R. et al. (1983), Summary of clinical trials of inactivated influenza vaccine. Rev. Infect. Dis., 5, 723-36.
2. Powers, D.C. et al. (1993), Effect of age on cytotoxic lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza vaccine. J. Infect. Dis., 167, 584-92.
3. + T cell differentiation in vivo. Clin. Exp. Immunol., 96, 528-534.
4. Kensil, C.R. et al. (1991), Separation and characterization of Saponins with adjuvant activity from Quillaja saponaria Molina Cortex. J. Immunol., 146, 431-37.
5. Payne, L.G. et al. (1995), Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery, in "Vaccine Design: The subunit and adjuvant approach". (Powell, MF, Newman, MJ). (pp. 473-93) Plenum Press, New York.
6. Lu, Y. et al. (1996), Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 12, 99-106.
7. Payne, L.G. et al. (1997), PCPP as a parenteral adjuvant for disease antigens. Dev. Biol. Stand., 92, 79-87.
8. Payne, L.G. et al. (1998), Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine, 16, 92-98.